Baxter International (BAX)

Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has appointed John Rogers as executive vice president and chief financial officer (CFO), reporting to Baxter president and chief executive officer (CEO), Andrew Hider, effective Oct. 1, 2026.

Baxter International Inc. (NYSE:BAX) (“Baxter” or the “Company”) today announced the pricing terms for its previously announced cash tender offers (each, an “Offer” and collectively, the “Offers”) of the Company's validly tendered (and not validly withdrawn) notes set forth below (the “Notes”) using a “waterfall” methodology under which the Company will accept the Notes in order of their respective acceptance priority levels noted in the table below (the “Acceptance Priority Levels”). The Offers are being made pursuant to an Offer to Purchase, dated Aug. 4, 2026, as amended by the Company’s press release relating to the early tender results and upsizing of the Offers issued on Aug. 18, 2026 (as it may be further amended or supplemented from time to time, the “Offer to Purchase”) which sets forth a description of the terms of the Offers. As previously announced, the Company has exercised its right to amend the terms of the Offers to increase the aggregate purchase price (excluding accrued and unpaid interest) (the “Offer Cap”) for all Notes validly tendered and accepted for purchase pursuant to the Offers from $500 million to $600 million.

Baxter International Inc. (NYSE:BAX) (“Baxter” or the “Company”) today announced the early results of its previously announced cash tender offers (each, an “Offer” and collectively, the “Offers”) for its validly tendered (and not validly withdrawn) notes set forth below (collectively, the “Notes”). The Offers are being made pursuant to an Offer to Purchase, dated Aug. 4, 2026 (as it may be amended or supplemented from time to time, the “Offer to Purchase”), which sets forth a description of the terms of the Offers.

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a...

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk tha...

Baxter has had an impressive run over the past six months as its shares have beaten the S&P 500 by 14.5%. The stock now trades at $27.42, marking a 26.2% gai...

Baxter International Inc. (NYSE:BAX) (“Baxter” or the “Company”) today announced that it has commenced cash tender offers (each, an “Offer” and collectively, the “Offers”) for the maximum principal amount of validly tendered (and not validly withdrawn) notes set forth below (collectively, the “Notes”), such that the aggregate purchase price, not including accrued and unpaid interest, payable in respect of such Notes will not exceed $500 million.

Baxter International (NYSE:BAX) reported second-quarter 2026 results that exceeded its expectations, supported by broad-based sales growth, strong demand in Advanced Surgery and drug compounding, and a $75 million tariff refund. The company raised its full-year organic sales-growth outlook and incre

The company's second-quarter performance was impressive.

What Happened? Shares of healthcare company Baxter International (NYSE:BAX) jumped 8.7% in the afternoon session after the company reported second-quarter re...

Healthcare company Baxter International (NYSE:BAX) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 5.3% year on year to...

Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the second quarter of 2026.

Healthcare company Baxter International (NYSE:BAX) will be reporting results this Thursday before market open. Here’s what you need to know. Baxter beat anal...

What Happened? Shares of healthcare company Baxter International (NYSE:BAX) jumped 3.6% in the afternoon session after TD Cowen raised its price target on th...

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to conv...

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...

Baxter trades at $22.13 and has moved in lockstep with the market. Its shares have returned 10% over the last six months while the S&P 500 has gained 8.7%. I...

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not...